Gadoxetate sodium(CAS: 135326-22-6)

Gadoxetate sodium (CAS: 135326-22-6) is a pharmaceutical agent used in medical imaging. It is subject to various regulatory guidelines including the REACH regulations in the European Union, FDA approval in the United States, and EPA regulations for environmental protection. The substance is classified under GHS (Globally Harmonized System of Classification and Labeling of Chemicals) as a category 2 respiratory sensitizer and category 1B dermal sensitiser.

There are several alternatives to Gadoxetate sodium (CAS: 135326-22-6) in the synthesis of contrast agents for medical imaging. Some common alternatives include Gadoteric acid and Gadodiamide. These compounds offer similar functions but may have different GHS classifications and regulatory requirements.

Gadoxetate sodium (CAS: 135326-22-6) continues to be an important contrast agent in the medical imaging market, particularly for hepatobiliary imaging. Research trends are focused on understanding its pharmacokinetics, improving safety profiles, and exploring new applications in liver and biliary system diagnostics. The demand for this compound is driven by its high specificity and safety in contrast-enhanced MRI.

Waste containing Gadoxetate sodium (CAS: 135326-22-6) should be collected in appropriate containers and disposed of according to local regulations. Professional waste disposal services are recommended to ensure compliance with environmental protection standards. Proper incineration or other specialized waste disposal methods should be employed, and all handling should follow safety guidelines to prevent exposure and environmental contamination.